Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
59.3M
-
Shares change
-
+10.2M
-
Total reported value, excl. options
-
$1.13B
-
Value change
-
+$194M
-
Put/Call ratio
-
0.08
-
Number of buys
-
101
-
Number of sells
-
-27
-
Price
-
$19.11
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2022
155 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q3 2022.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.3M shares
of 120M outstanding shares and own 49.36% of the company stock.
Largest 10 shareholders include FMR LLC (8.93M shares), Frazier Life Sciences Management, L.P. (8.68M shares), BlackRock Inc. (5.08M shares), Point72 Asset Management, L.P. (3.79M shares), Bain Capital Life Sciences Investors, LLC (3M shares), ORBIMED ADVISORS LLC (2.8M shares), STATE STREET CORP (2.66M shares), VANGUARD GROUP INC (2.25M shares), PICTET ASSET MANAGEMENT SA (1.6M shares), and Logos Global Management LP (1.53M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.